View Post

Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Business Wire From: Genexine, Inc. (Genexine) and NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the first patient has been dosed in a combination regimen trial to investigate the safety and efficacy of Hyleukin-7™, their T cell amplifier, in combination with Merck’s anti PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with refractory or relapsed triple-negative breast …